PDC*line Pharma will be presenting a poster at the 2022 ESMO Immuno-Oncology Annual Congress
PDC*line Pharma will be presenting a poster at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress taking place from 7 to 9 December 2022, in Geneva, Switzerland. The poster will highlight immunological data from patients enrolled in the three first cohorts of the on-going Phase I/II trial evaluating PDC*lung01, an 'off-the-shelf' cancer vaccine for the treatment of patients with non-small cell lung cancer (NSCLC).
Title: The therapeutic cancer vaccine PDC*lung01 induces immune responses with or without anti PD-1 treatment in patients with non-small cell lung cancer
. Abstract Number: 202P
· Presentation Topic: Tumour biology and tumour microenvironment
· Session Time: 8 December, 12:30-13:15
· Location: Palexpo exhibition centre – Foyer Mezzanine
· Speaker: Dr. Anne Sibille (Liège, Belgium)
Link to the abstract: https://lnkd.in/gDdJ9eCT
The poster will be available on the Publications section of pdc-line-pharma.com following the presentation.
About ESMO and ESMO I-O
ESMO is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information.
The ESMO Immuno-Oncology Congress is a global meeting offering an advanced educational programme and the latest scientific developments in this promising field.
